| Arnes L*, Liu Z, Wang J, Carlo Maurer H, Sagalovskiy I, Sanchez-Martin M, Bommakanti N, Garofalo DC, Balderes DA, Sussel L, Olive KP, Rabadan R. “Comprehensive characterisation of compartment-specific long non-coding RNAs associated with pancreatic ductal adenocarcinoma”, Gut, Feb 2018, advance online. PMID: 29440233 Role: Oversaw laboratory component and contributed large-scale RNA-seq dataset; writing and editing. |
| Payen T, Palermo CF, Sastra SA, Chen H, Han Y, Olive KP,* Konofagou EE.* “Elasticity mapping of murine abdominal organs in vivo using harmonic motion imaging (HMI).” Phys Med Biol, 61(15): 5741-54, 2016. PMID: 27401609. Role: Oversaw in vivo studies and analysis of tissues; writing and editing. |
| Rhim AD*, Oberstein PE*, Thomas DH*, Mirek ET, Palermo CF, Sastra SA, Dekleva EN, Saunders T, Becerra CP, Tattersall IW, Westphalen CB, Kitajewski J, Fernandez-Barrena MG, Fernandez-Zapico ME, Iacobuzio-Donahue C, Olive KP, Stanger BZ. Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma. Cancer Cell. 2014 May 21. pii: S1535-6108(14)00184-6. doi: 10.1016/j.ccr.2014.04.021. [Epub ahead of print] PMID: 24856585 |
| Olive KP1, Politi K. Translational therapeutics in genetically engineered mouse models of cancer. Cold Spring Harb Protoc. 2014 Feb 1;2014(2):131-43. doi: 10.1101/pdb.top069997. |
| Sastra SA, Olive KP. Acquisition of Mouse Tumor Biopsies through Abdominal Laparotomy. Cold Spring Harb Protoc. 2014 Jan 1;2014(1). pii: pdb.prot077834. doi: 10.1101/pdb.prot077834. PMID:24371318 |
| Delgiorno KE, Hall JC, Takeuchi KK, Pan FC, Halbrook CJ, Washington MK, Olive KP, R Spence J, Sipos B, Wright CV, Wells JM, Crawford HC. Identification and Manipulation of Biliary metaplasia in pancreatic tumors. Gastroenterology. 2014 Jan;146(1):233-244.e5. doi: 10.1053/j.gastro.2013.08.053. Epub 2013 Aug 30. PMID:23999170 |
| Oberstein PE, Olive KP.Pancreatic Cancer: why is it so hard to treat. Therap Adv Gastroenterol. 2013 Jul;6(4):321-37. doi: 10.1177/1756283X13478680. PMID:23814611 |
| Chin L, de Sauvage F, Egeblad M, Olive KP, Tuveson D, Weiss W.Recapitulating Human cancer in a mouse. Nat Biotechnol. 2013 May;31(5):392-5. doi: 10.1038/nbt.2575. No abstract available. PMID:23657389 |
| Sastra SA, Olive KP. Quantification of murine pancreatic tumors by high resolution ultrasound. Methods Mol Biol. 2013;980:249-66. doi: 10.1007/978-1-62703-287-2_13. PMID:23359158 |
| Westphalen CB, Olive KP. Genetically engineered mouse models of pancreatic cancer. Cancer J. 2012 Nov-Dec;18(6):502-10. doi: 10.1097/PPO.0b013e31827ab4c4. Review. PMID:23187836 |
| Cox AD, Olive KP. Silencing the killers: paracrine immune suppression in pancreatic cancer. Cancer Cell. 2012 Jun 12;21(6):715-6. doi: 10.1016/j.ccr.2012.05.029. PMID: 22698396 |
| Bapiro TE, Richards FM, Goldgraben MA, Olive KP, Madhu B, Frese KK, Cook N, Jacobetz MA, Smith DM, Tuveson DA, Griffiths JR, Jodrell DI. A novel method for quantification of gemcitabine and its metabolites 2',2'-difluorodeoxyuridine and gemcitabine triphosphate in tumour tissue by LC-MS/MS: comparison with (19)F NMR spectroscopy. Cancer Chemother Pharmacol, March 23, 2011. PMID:21431415 |
| Neesse A, Michl P, Frese KK, Feig C, Cook N, Jacobetz MA, Lolkema MP, Buchholz M, Olive KP, Gress TM, Tuveson DA. Stromal biology and therapy in pancreatic cancer.Gut. 2011 Jun;60(6):861-8. doi: 10.1136/gut.2010.226092. Epub 2010 Oct 21. Review. PMID: 20966025 |
| Skoulidis F, Cassidy LD, Pisupati V, Jonasson JG, Bjarnason H, Eyfjord JE, Karreth FA, Lim M, Barber LM, Clatworthy SA, Davies SE, Olive KP, Tuveson DA, Venkitaraman AR. Germline Brca2 heterozygosity promotes Kras(G12D)-driven carcinogenesis in a murine model of familial pancreatic cancer. Cancer Cell, 18(5):499-509, 2010. PMID:21056012 |
| Olive KP, Davidson CJ, Jacobetz MA, Honess D, McIntyre D, Madhu B, Goldgraben MA, Frese K, Caldwell ME, DeNicola G, Feig C, Gopinathan A, Combs C, Winter SP, Ireland H, Wang L, Rückert F, Grützmann R, Pilarsky C, Izeradjene K, Hingorani SR, Huang P, Davies SE, Iacobuzio-Donahue C, Plunkett W, Egorin M, Hruban RH, McGovern K, Griffiths J, Tuveson DA. Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer. Science, 324: 1457-1461, 2009. PMID:19460966 |
| Bertout JA* & Patel JA*, Fryer BH, Durham AC, Covello KA, Olive KP, Goldschmidt MH, Simon, MC. Heterozygosity for Hypoxia Inducible Factor 1a decreases the incidence of thymic lymphosarcomas in a p53 mutant mouse model. Cancer Research, 69(7): 3213- 3220, 2009. PMID:19293180 |
| Cook N, Olive KP, Frese K, Tuveson DA. K-ras-driven pancreatic cancer mouse model for anticancer inhibitor analyses. Methods in Enzymology, 439: 73 – 85. PMID:18374157 |
| Olive KP, Tuveson DA. The use of targeted mouse models for preclinical testing of novel cancer therapeutics. Clin Cancer Res. 2006 Sep 15;12(18):5277-87. Review. PMID: 17000660 |
| Jackson EL* & Olive KP*, Tuveson DA, Bronson R, Crowley D, Brown M, Jacks T. The Differential Effects of Mutant p53 Alleles on Advanced Murine Lung Cancer. Cancer Research, 65(22): 10280-10288, 2005. PMID:15607980 |
| Wijnhoven SW, Zwart E, Speksnijder EN, Beems RB, Olive KP, Tuveson DA, Jonkers J, Schaap MM, van den Berg J, Jacks T, van Steeg H, de Vries A. Mice Expressing a Mammary Gland-Specific R270H Mutation in the p53 Tumor Suppressor Gene Mimic Human Breast Cancer Development. Cancer Research, Vol. 65 (18): 8166 – 8173, 2005. PMID:16166291 |
| Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, Crowley D, Jacks T. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell. 2004 Dec 17;119(6):847-60. PMID: 15607980 |